DGAP-Adhoc: Limes Schlosskliniken AG: Audited consolidated financial statements 2021 / Approval and adoption of the consolidated financial statements per 31.12.2021 of LIMES Schlosskliniken
DGAP-Ad-hoc: Limes Schlosskliniken AG / Key word(s): Annual Results/Forecast
Limes Schlosskliniken AG: Audited consolidated financial statements 2021 / Approval and adoption of the consolidated financial statements per 31.12.2021 of LIMES Schlosskliniken
29-Apr-2022 / 15:52 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP-Adhoc: Limes Schlosskliniken AG:
Audited consolidated financial statements 2021 / Approval and adoption of the consolidated financial statements per 31.12.2021 of LIMES Schlosskliniken
Cologne, April 29, 2022: At its meeting today, the Supervisory Board of LIMES Schlosskliniken AG approved the 2021 consolidated financial statements audited by the auditing company B-S-H Collegen GmbH. Compared to the preliminary financial results (unaudited) published on 18 January 2022, the Paracelsus Recovery Clinic acquired in 2021 has now been included in the audited consolidated financial statements. This results in the following changed financial results:
- Sales Revenue EUR 23.4m; (p. y. EUR 11.0m) + 112.7%
- Total Revenue: 25.2 Mio. EUR (p. y. EUR 11.2m) + 125.7 %
- Gross earnings (EBITDA) +6,015 kEUR; (p. y. +838 kEUR)
- Operating result (EBIT) + 4,530 kEUR; (p. y. -427 kEUR)
- Earnings before taxes (EBT) +4,305 kEUR; (Vj. -691 kEUR)
- Earnings after minorities and after taxes (EAT) 3,944 kEUR; (Vj. -694 TEUR)
- Earnings per share 13.45 kEUR; (Vj. -2.37 kEUR)
We assume that we will be able to further increase capacity utilisation at the existing locations in the current 2022 financial year. According to the current state, we are planning to open the new LIMES Schlossklinik "Bergisches Land" in Lindlar near Cologne on 01.09.2022. Due to compensation payments caused by project delays, the planned start-up losses should not occur in the previous form. Our revenue and earnings forecasts for 2022 are in the range of EUR 27m with an operating result (EBITDA) of approximately EUR 8m.
Short profile: The LIMES Schlosskliniken Group operates high-quality private clinics in Germany for stress-related illnesses, mental and emotional disorders, such as depression, affective disorders and acute burnout conditions. The range of services is primarily aimed at private patients, self-payers and international clients, but also patients with public insurance by way of cost reimbursement. The LIMES Schlosskliniken Group stands for the special approach of a relationship-oriented medicine in the treatment of people with mental illnesses. In addition to top medical quality, patients are offered a unique, protected and healing environment in which they can recover holistically. Further information is available at www.limes-schlosskliniken.de.
Your contact person:
LIMES Schlosskliniken AG, Petra Kaes, Investor Relations
Kaiser-Wilhelm-Ring 26, 50672 Cologne
Tel.: 02203 / 29014-202, [email protected], www.limes-schlosskliniken.de
Language: English
Company: LIMES Schlosskliniken AG,Kaiser-Wilhelm-Ring 26, 50672 Köln, Germany
Phone: 49 2203 29014-202
Fax: 49 2203 29014-201
Email: [email protected]
Internet: www.limes-schlosskliniken.de
ISIN: DE000A0JDBC7
WKN: AOJDBC
Stock exchange Düsseldorf Freiverkehr, Primärmarkt, XETRA
End of the message
29-Apr-2022 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
|
Language: |
English |
Company: |
Limes Schlosskliniken AG |
|
Kaiser-Wilhelm-Ring 26 |
|
50672 Köln |
|
Germany |
ISIN: |
DE000A0JDBC7 |
WKN: |
A0JDBC |
Listed: |
Regulated Unofficial Market in Dusseldorf |
EQS News ID: |
1340145 |
|
End of Announcement |
DGAP News Service |
1340145 29-Apr-2022 CET/CEST
Die wichtigsten Finanzdaten auf einen Blick
|
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
Umsatzerlöse1 |
6,54 |
7,43 |
8,18 |
11,02 |
23,44 |
28,81 |
37,17 |
EBITDA1,2 |
-0,49 |
-0,13 |
0,26 |
0,84 |
6,02 |
8,65 |
7,67 |
EBITDA-Marge3 |
-7,49 |
-1,75 |
3,18 |
7,62 |
25,68 |
30,02 |
|
EBIT1,4 |
-0,72 |
-0,93 |
-0,54 |
-0,43 |
4,53 |
6,00 |
5,03 |
EBIT-Marge5 |
-11,01 |
-12,52 |
-6,60 |
-3,90 |
19,33 |
20,83 |
13,53 |
Jahresüberschuss1 |
-1,25 |
-1,46 |
-0,83 |
-0,69 |
4,11 |
4,86 |
3,91 |
Netto-Marge6 |
-19,11 |
-19,65 |
-10,15 |
-6,26 |
17,53 |
16,87 |
10,52 |
Cashflow1,7 |
1,02 |
-0,66 |
0,17 |
0,76 |
4,77 |
8,04 |
6,29 |
Ergebnis je Aktie8 |
-4,95 |
-5,78 |
-2,81 |
-2,37 |
13,45 |
14,34 |
11,58 |
Dividende8 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
Quelle: boersengefluester.de und Firmenangaben
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: B-S-H Collegen
|
INVESTOR-INFORMATIONEN |
©boersengefluester.de |
Limes Schlosskliniken |
WKN |
Kurs in € |
Einschätzung |
Börsenwert in Mio. € |
A0JDBC |
332,000 |
Kaufen |
97,34 |
KGV 2025e |
KGV 10Y-Ø |
BGFL-Ratio |
Shiller-KGV |
19,64 |
21,39 |
0,91 |
70,29 |
KBV |
KCV |
KUV |
EV/EBITDA |
6,43 |
15,47 |
2,62 |
12,89 |
Dividende '22 in € |
Dividende '23 in € |
Div.-Rendite '23 in % |
Hauptversammlung |
0,00 |
0,00 |
0,00 |
10.06.2024 |
Q1-Zahlen |
Q2-Zahlen |
Q3-Zahlen |
Bilanz-PK |
|
03.09.2024 |
|
13.05.2024 |
Abstand 60Tage-Linie |
Abstand 200Tage-Linie |
Performance YtD |
Performance 52 Wochen |
-6,32% |
-5,06% |
16,90% |
23,88% |
|
|